Devyser Diagnostics
Devyser Diagnostics AB develops, manufactures and sells diagnostic solutions and analysis services for clinical genetics and transplant laboratories. Its portfolio is built around proprietary genetic testing products used for hereditary disease, oncology and transplant patient monitoring, with operations centered in Stockholm and sales in more than 65 countries.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueProprietary genetic tests used to diagnose inherited disorders and related conditions.
Tests and workflows for donor matching, post-transplant follow-up and monitoring.
Genetic testing solutions used to support targeted cancer treatment decisions.
Support services and analysis offerings for clinical genetics laboratories.
Data processing, analysis software and integrated laboratory workflow tools.
Customers
Devyser sells primarily to clinical genetics laboratories and transplant laboratories that need reliable, fast and standardized genetic testing workflows. It also serves research-oriented laboratories and, in some markets, reaches end customers through distributors and strategic partners such as Thermo Fisher. Customers buy Devyser’s products to simplify complex analyses, reduce hands-on work and improve turnaround times for patient diagnosis and follow-up.
Buy genetic testing products and workflows to diagnose inherited diseases and improve lab throughput
Buy transplant-related assays for donor matching and post-transplant monitoring
Use hereditary cancer and related assays to support treatment decisions
Purchase or distribute products to extend reach in local markets and support customer service
Use products in validation, clinical studies and specialized diagnostic workflows
Strategy
Devyser’s strategy centers on becoming a primary partner for clinical genetics laboratories through integrated workflows, scientific collaboration and technical support. It also emphasizes portfolio optimization, operational efficiency and targeted investment in innovation, digitalization and automation to support scalable growth and long-term competitiveness.
Integrated workflows and support services increase customer stickiness and broaden the company’s role in the lab
Channel partners accelerate penetration in new and existing markets without building full direct sales coverage everywhere
Focusing resources on higher-potential assays improves product-market fit and supports scalable growth
Regulatory approvals are essential for commercialization and broader market access
Geography
Devyser sells its products in more than 65 countries, with direct sales in selected markets and distributor-led sales elsewhere. Production, research and development are primarily based in Stockholm, while R&D also includes personnel in Italy, making the company operationally anchored in Europe but commercially global.
Risks
Devyser faces product, regulatory and market-access risks typical of diagnostics companies, including competition from large multinational suppliers and laboratory-developed tests. Its business is also exposed to cybersecurity, trade frictions, currency movements and financing risk because it operates internationally, relies on regulated products and has historically depended on external funding.
- Competition from multinational diagnostics firms and home-brew testsImpact: HighLikelihood: High
Customers can choose established brands or in-house laboratory methods
Exposure: Clinical genetics and transplant labs
- Future financing riskImpact: HighLikelihood: High
If cash generation is insufficient, the company may need external capital to fund development
Exposure: Product development and expansion plans
- Product portfolio design riskImpact: HighLikelihood: Medium
If products do not match customer needs or technology trends, customers may switch to alternatives
Exposure: Genetic testing and transplant diagnostics portfolio
- Regulatory and market access riskImpact: HighLikelihood: Medium
Products need approvals and reimbursement acceptance before launch in many countries
Exposure - Cybersecurity and data riskImpact: HighLikelihood: Medium
Lab and company systems handle sensitive information and operational data
Exposure - Trade and tariff riskImpact: MediumLikelihood: Low
International sourcing and freight can become more expensive or complex
Exposure: Cross-border procurement and distribution
Accounting
Judgemental itemsSales through distributors and partnerships can affect when revenue is recognized
Impact: Channel and geography mix may shift quarterly revenue patterns
Product development is central to the business and may involve judgment on expense vs asset treatment
Impact: Affects operating profit and intangible asset balances
Portfolio reviews and regulatory changes can affect recoverability of capitalized assets
Impact: Could lead to write-downs if products underperform
International sales and operations create currency exposure and valuation effects
Impact: Can move reported earnings and equity
Similar listed companies
Publicly listed companies with a comparable business focus.
Insight Molecular Diagnostics Inc.
IMDX · In Vitro & In Vivo Diagnostic Substances
CareDx, Inc.
CDNA · Services-Medical Laboratories
Veracyte, Inc
VCYT · Services-Medical Laboratories
Veracyte is a U.S.-based molecular diagnostics company that develops and commercializes genomic tests used in cancer and other disease areas.
Boule Diagnostics
BOUL · Health Care
Boule Diagnostics AB is a global diagnostics company specializing in near-patient, decentralized blood diagnostics.
Biodesix, Inc
BDSX · Services-Medical Laboratories
Biodesix is a U.S.-based diagnostic solutions company focused on lung disease testing and diagnostic development services.
SOPHiA Genetics SA
SOPH · Services-Computer Processing & Data Preparation
SOPHiA GENETICS SA is a Switzerland-based healthcare technology company that provides a cloud-native data analytics platform for interpreting complex medical and genomic datasets.
Last updated: 24/09/2026